This technology is a preconditioning regimen for mesenchymal stem cells prior to immunotherapy.
Mesenchymal stem cells (MSCs) are evolving as a promising cell-based therapy for a wide range of immune-related disorders, as they have been shown to possess immunosuppressive and hypoimmunogenic properties. MSC-based immunotherapy has shown limited efficacy in clinical trials, compared to in vitro studies.. Despite preconditioning methods, the mesenchymal stem cells used for treatment have unstable immunosuppressive action. There is a need for an improved stem cells preconditioning regimen for immunomodulatory and immunosuppressive applications.
This technology is a method to enhance clinical efficacy of cell-based immunotherapy. It combines two preconditioning methods: exposure to hypoxia and to an inflammatory cytokine, to increase the immunosuppressive potential of mesenchymal stem cells. The dual-treatment priming regimen confers greater cellular improvements and less dependence on oxidative phosphorylation indicative of enhanced immunoregulatory functions and increased therapeutic potential.
This technology has been validated in vitro.
Gordana Vunjak-Novakovic, Ph.D.
IR CU18179, CU18259
Licensing Contact: Devin Jones
